10 September 2020
Pfizer and BioNTech have reported positive preliminary preclinical data of their lead Covid-19 vaccine candidate, BNT162b2, in mouse and non-human primate models. In a non-human primate preclinical study, BNT162b2 was able to protect rhesus macaques against Covid-19. The vaccine candidate triggered SARS-CoV-2 neutralising antibodies in vaccinated-macaques, along with viral antigen-specific CD4+ and CD8+ T cells.
The Russian Direct Investment Fund (RDIF) has teamed up with pharmaceutical company Landsteiner Scientific to supply 32 million doses of the Russian Sputnik V vaccine to Mexico. Deliveries are set to begin in November 2020, subject to Mexican regulatory approvals.
China-based Sinovac Biotech has reported positive data from healthy adults aged 60 and above in Phase I/II clinical trials of its inactivated Covid-19 vaccine candidate, CoronaVac. According to the results, the vaccine showed good safety and immunogenicity, which was comparable to that observed in healthy adults aged 18 to 5 in the prior studies. Sinovac noted that CoronaVac appeared to be well tolerated across low dose, medium dose and high dose groups. Investigators did not report any vaccine-related serious adverse event.
Dasa has signed a letter of intent with United Biomedical subsidiary COVAXX to jointly conduct a large-scale human efficacy clinical trial of the latter's Covid-19 vaccine candidate in Brazil. COVAXX will provide Dasa with its experimental s UB-612 vaccine for a Phase II/III clinical trial in Brazil. UB-612 is a synthetic multitope peptide-based Covid-19 vaccine candidate.